{"type":"profile","id":"profile=medica2026.3086283","exhSeoId":"reSEgke8TbuDYmMKpYpWkQ","name":"J R Biomedical Ltd","email":"bd@jrbiomed.com","getInTouchEmail":"bd@jrbiomed.com","profileAddress":{"address":["Optic Technology Centre St Asaph Business Park"],"city":"St Asaph","zip":"LL17 0JD","country":"United Kingdom of Great Britain and Northern Ireland","countryCode":"GB"},"phone":{"phone":"+44 1745 535207"},"links":[{"id":"link=fh8iQx9SRGO2J7FAZnRP6g","type":"link","link":"https://jrbiomed.com","parentType":"profile","order":1,"visibleInLang":["en","de"]}],"media":[],"locations":[{"areaId":"16","area":"Hall 16","stand":"J06"}],"location":"Hall 16 / J06","locationIsVirtual":false,"events":[{"key":"medica2026","label":"MEDICA 2026"}],"eventIcons":[{"label":"MEDICA 2026","src":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png"}],"eventMap":"https://iahapla02.messe-duesseldorf.de/en/2dexgroundV2/medica2026/3086283.svg","areaMap":"https://iahapla02.messe-duesseldorf.de/en/3dhallV2/medica2026/16/3086283.svg","areaId":"16","premium":false,"exhIsLead":false,"logoUploadedByPubimport":false,"tags":[],"xtags":[],"socialMedia":[],"synonyms":[],"text":"<p><em>With applications in sepsis and inflammation, we have developed in cooperation with Cardiff University, a 10 minute rapid test and proprietary  panel of monoclonal and polyclonal antibodies, that detect the innate immune system biomarker soluble Toll-like receptor 2 (sTLR2).</em></p><p><br></p><ul><li>UKCA certified</li><li>ISO13485:2016 certified</li><li>Results in 10 minutes</li><li>20µL blood sample</li></ul><p><br></p><p>J R Biomedical Ltd. is a British ISO13485 certified <em>in-vitro</em> diagnostics company who have developed a panel of proprietary antibodies, and a rapid diagnostic IVD to detect plasma soluble Toll-like receptor 2 (sTLR2), a biomarker known to be elevated in sepsis. UK Patent Application GB2502531.3. </p><p><br></p><p>An independent study of sTLR2 versus CRP in critically ill patients showed that sTLR2 had better specificity and sensitivity for sepsis than C-reactive protein, the most commonly used marker in the ICU. Further, low sTLR2 levels had good ability to rule out sepsis within the first 12 h of ICU stay, when clinical parameters and traditional markers of infection are often equivocal. </p>","pdfs":[],"tol":[],"categories":[{"id":"prod=medica2026.01.02.03","label":"Microbiology & infectious disease diagnostics","catalogIndex":"01.02.03","eventIcons":[{"key":"medica2026","small":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-SzHinHZFRDix2fwVNyP4ag.png","tiny":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png","label":"MEDICA 2026"}],"productList":[{"id":"prodinfo=60NNB2FnR9ahmzX9xeCu1Q","label":"sTLR2 RAPID Test with applications in sepsis and inflammation"}],"hierarchy":[{"id":"01","label":"Clinical Diagnostics & Therapeutic Technologies"},{"id":"01.02","label":"Laboratory, IVD & Diagnostics"},{"id":"01.02.03","label":"Microbiology & infectious disease diagnostics"}]}],"write":false,"lastModified":"2026-11-03T21:07:21Z","tagsAreEditable":false,"xtagsAreEditable":false,"isGetInTouchAllowed":false}